MetaVia Doses First Patient in Higher-Dose DA-1726 GLP-1/Glucagon Dual Agonist Phase 1 Study
MetaVia dosed the first patient in a higher-dose Phase 1 study of DA-1726, its GLP-1 and glucagon dual agonist for obesity treatment, marking continued advancement in next-gen weight loss drugs.